quinazolines has been researched along with Salivary Gland Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastida, CC; Falchook, GS; Kurzrock, R; Lippman, SM | 1 |
| Blumenschein, GR; El-Naggar, AK; Glisson, BS; Gonzalez-Angulo, AM; Jakob, JA; Kies, MS; Kupferman, ME; Lee, JJ; Liu, DD | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Deluca, KA; Jaskoll, T; Melnick, M | 1 |
| Agulnik, M; Chen, EX; Cohen, EE; Cohen, RB; Dancey, J; Hayes, DN; Ho, J; Hotte, S; Laurie, S; Pond, GR; Siu, LL; Tsao, MS; Vidal, L; Winquist, E | 1 |
| Azuma, T; Fujishiro, Y; Matsuzaka, K; Ochiai, H; Tonogi, M; Yamane, GY | 1 |
| Cai, Y; Chen, G; Jia, J; Liu, B; Liu, H; Liu, JY; Zhang, JL; Zhang, W; Zhao, YF; Zhong, HY | 1 |
| Amjad, EH; Dibbley, SK; Lonardo, F; Piechocki, MP; Yoo, GH | 1 |
| Laurie, SA; Licitra, L | 1 |
| Agulnik, M; Brown, S; Chen, EX; Cohen, EW; Cohen, RB; Dancey, JE; Daneshmand, M; Hayes, DN; Ho, J; Hotte, SJ; Laurie, S; Lorimer, I; Pond, GR; Siu, LL; Tsao, MS; Vokes, EE; Winquist, E | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Kimpe, M; Nuyts, S; Prenen, H | 1 |
3 review(s) available for quinazolines and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
4 trial(s) available for quinazolines and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Infusions, Intravenous; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Receptor, ErbB-2; Reference Values; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Disease-Free Survival; Epidermal Growth Factor; Female; Follow-Up Studies; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Salivary Gland Neoplasms; Treatment Outcome | 2007 |
5 other study(ies) available for quinazolines and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lapatinib; Male; Middle Aged; Neoplasm, Residual; Quinazolines; Receptor, ErbB-2; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab; Vascular Endothelial Growth Factor A | 2014 |
CMV-induced pathology: pathway and gene-gene interaction analysis.
Topics: Animals; Carcinoma, Mucoepidermoid; Cytomegalovirus; Cytomegalovirus Infections; Epistasis, Genetic; Female; Gefitinib; Gene Expression Regulation; Gene Regulatory Networks; Humans; Mice; Mice, Inbred C57BL; Models, Theoretical; Organ Culture Techniques; Protein Kinase Inhibitors; Quinazolines; Salivary Gland Neoplasms; Salivary Glands; Signal Transduction; Tumor Microenvironment | 2014 |
The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salivary Gland Neoplasms; Side-Population Cells | 2012 |
Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma.
Topics: Animals; Anoikis; Antineoplastic Agents; Apoptosis; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Salivary Gland Neoplasms; Snail Family Transcription Factors; Transcription Factors | 2012 |
Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Acinar Cell; Caspases; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; fas Receptor; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Neoplasm Proteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Salivary Gland Neoplasms; Signal Transduction; Up-Regulation | 2006 |